The Manila Times

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data ...
PharmiWeb

Urology Devices Market Growth - Market Analysis, Size, Share, Trends, Demand, Overview and Segment Forecast To 2029

Global Urology Devices Market OverviewThe global urology devices market is poised for steady expansion and is projected to grow at a CAGR of approximately 6–7% during the forecast period from 2024 to ...

Myriad Genetics, Inc.: Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.F ...
Santé log

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin ...